Wuxi Biologics (Cayman) (HK:2269) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
WuXi Biologics (Cayman) Inc., a global biologics CRDMO platform, has issued a voluntary announcement regarding the passage of a U.S. House Draft Bill labeling the company as a ‘biotechnology company of concern.’ The bill, which includes a grandfather clause, is yet to be reviewed by the U.S. Senate and could be subject to changes. The company asserts that it does not pose a security risk, does not deal with human genomics data, and will continue to comply with international laws while monitoring the legislative process.
For further insights into HK:2269 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money